Merck profit beats, coronavirus uncertainty weighs on forecast

Merck & Co Inc beat analysts’ estimates for quarterly profit on Tuesday on strong demand for its blockbuster cancer drug, Keytruda, but expects coronavirus-led lockdowns to weigh on the treatment’s sales in the next few quarters.